Evidence for the existence of a histamine H2-receptor in the mouse thyroid. 1977

T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu

The existence of a histamine H2-receptor in the thyroid was investigated. Histamine in vitro stimulated the formation of cyclic AMP and colloid droplet formation in mouse thyroid lobes. Stimulation by histamine of cyclic AMP formation in mouse thyroid lobes was significantly inhibited by metiamide, a histamine H2-receptor antagonist. 4-Methylhistamine, a histamine H2-receptor agonist, markedly stimulated cyclic AMP formation, whereas 2-methylhistamine, a histamine H1-receptor agonist, was ineffective. The stimulation by 4-methylhistamine of cyclic AMP formation was markedly inhibited by metiamide, but not by chlorpheniramine, a histamine H1-receptor antagonist. In contrast, metiamide did not affect cyclic AMP formation induced either by TSH or by the long-acting thyroid stimulator. Therefore, it is suggested that there exists a histamine H2-receptor in the membranes of the thyroid follicular cells which facilitate thyroid hormone secretion via the adenylate cyclase-cyclic AMP system.

UI MeSH Term Description Entries
D007545 Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. Isoprenaline,Isopropylarterenol,4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol,Euspiran,Isadrin,Isadrine,Isopropyl Noradrenaline,Isopropylnoradrenaline,Isopropylnorepinephrine,Isoproterenol Hydrochloride,Isoproterenol Sulfate,Isuprel,Izadrin,Norisodrine,Novodrin,Hydrochloride, Isoproterenol,Noradrenaline, Isopropyl,Sulfate, Isoproterenol
D008135 Long-Acting Thyroid Stimulator An immunoglobulin G, often found in the blood of hyperthyroid individuals. It stimulates the thyroid for a longer duration than does thyrotoxin and may cause hyperthyroidism in newborns due to placental transmission. LATS,Thyroid Stimulating Hormone Receptor Autoantibodies,Thyroid Stimulating Hormone Receptor Autoantibody,Thyroid Stimulator, Long-Acting,Thyrotropin Receptor Antibodies,Thyrotropin Receptor Antibody,Thyrotropin Receptor Autoantibodies,Thyrotropin Receptor Autoantibody,Antibody, Thyrotropin Receptor,Autoantibody, Thyrotropin Receptor,Long Acting Thyroid Stimulator,Receptor Antibody, Thyrotropin,Receptor Autoantibody, Thyrotropin,Thyroid Stimulator, Long Acting
D008297 Male Males
D008761 Methylhistamines Histamine substituted in any position with one or more methyl groups. Many of these are agonists for the H1, H2, or both histamine receptors.
D008785 Metiamide A histamine H2 receptor antagonist that is used as an anti-ulcer agent. Metiamide Monohydrochloride,SK&F-92058,SKF-92058,Monohydrochloride, Metiamide,SK&F 92058,SK&F92058,SKF 92058,SKF92058
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011968 Receptors, Histamine Cell-surface proteins that bind histamine and trigger intracellular changes influencing the behavior of cells. Histamine receptors are widespread in the central nervous system and in peripheral tissues. Three types have been recognized and designated H1, H2, and H3. They differ in pharmacology, distribution, and mode of action. Histamine Binding Sites,Histamine Receptors,Histamine Receptor,Binding Sites, Histamine,Receptor, Histamine,Sites, Histamine Binding
D011970 Receptors, Histamine H2 A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine H2 receptors act via G-proteins to stimulate ADENYLYL CYCLASES. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (From Biochem Soc Trans 1992 Feb;20(1):122-5) Histamine H2 Receptors,H2 Receptors,Receptors, H2,H2 Receptors, Histamine
D002744 Chlorpheniramine A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE. Chlorphenamine,Chlorprophenpyridamine,Aller-Chlor,Antihistaminico Llorens,Chlo-Amine,Chlor-100,Chlor-Trimeton,Chlor-Tripolon,Chlorpheniramine Maleate,Chlorpheniramine Tannate,Chlorpro,Chlorspan 12,Chlortab-4,Cloro-Trimeton,Efidac 24,Kloromin,Piriton,Teldrin,Maleate, Chlorpheniramine,Tannate, Chlorpheniramine
D004705 Endocytosis Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis. Endocytoses

Related Publications

T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
January 1979, The Journal of pharmacy and pharmacology,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
January 1981, Pharmacology,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
September 1977, The American journal of physiology,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
October 1979, Agents and actions,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
November 1979, British journal of pharmacology,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
June 1994, Drugs,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
January 1991, Drug design and delivery,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
March 1978, British journal of pharmacology,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
January 1980, British journal of pharmacology,
T Onaya, and K Hashizume, and A Sato, and K Takazawa, and F Akasu
March 1996, The Journal of biological chemistry,
Copied contents to your clipboard!